The Journal of
Clinical Psychiatry

Suicide

Academic Highlights September 15, 2003

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders.

J Clin Psychiatry 2003;64(9):1122-1129

Article Abstract

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders. [CME]

Buy PDF for $40.00

Please sign in or purchase this PDF for $40.00.

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD

View current Issue